Onco360, a leading independent specialty pharmacy, has been selected as a national pharmacy partner for VEPPANU (vepdegestrant), a new FDA-approved treatment for advanced or metastatic ER-positive, HER2-negative breast cancer with ESR1 mutation. VEPPANU works by degrading estrogen receptors in cancer cells and showed significant improvement in progression-free survival in a Phase 3 trial compared to fulvestrant. This partnership aims to improve patient access to this innovative therapy while providing personalized clinical support. Onco360 is part of PharMerica Corporation and serves oncology patients nationwide through its accredited pharmacy network.
Interim results from the Phase 3 DASL-HiCaP trial show that adding darolutamide to standard androgen deprivation therapy (ADT) and radiation therapy reduces the risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence...
Anthropic reported a massive increase in revenue, reaching $16.3 billion in the first half of 2026 compared to just $1.1 billion in the same period last year. This surge highlights rapid growth and strong demand for its products or services. The dram...
Tower Semiconductor is entering a new growth phase fueled by Silicon Photonics, securing $1.3 billion in contracts for 2027 and $290 million in pre-payments. In Q2 2026, the company reported revenue of $460 million, a 23.7% increase year-over-year, w...
The Bitget hacker has transferred $19.48 million, mostly in Bitcoin, across 52 transactions as tracked by blockchain intelligence firm Arkham. Since October 15, a total of $78.01 million has moved to new addresses linked to the September breach, whic...
A crypto commentator highlighted that historically, 92% of nine-month periods after U.S. midterm elections have seen market gains, averaging 19%, with the only negative period during the Great Depression. This pattern suggests potential positive mome...
